Ravindran Kanesvaran

11 Hospital Crescent
Singapore, 169610, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 244 publications

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Journal: Expert opinion on biological therapy

Published: August 29, 2026

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Journal: Minerva urology and nephrology

Published: April 23, 2026

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).

Journal: ESMO open

Published: April 21, 2026

Empowering Patients: The Role of Shared Treatment Decision-Making in Advanced Bladder Cancer-A Podcast.

Empowering Patients: The Role of Shared Treatment Decision-Making in Advanced Bladder Cancer-A Podcast.

Journal: Advances in therapy

Published: April 15, 2026

Cancer incidence and mortality among older adults in Asia: Estimates for 2022 and projections to 2050.

Cancer incidence and mortality among older adults in Asia: Estimates for 2022 and projections to 2050.

Journal: Cancer epidemiology

Published: February 04, 2026

Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.

Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.

Journal: Cancer research communications

Published: January 23, 2026

Early EGFR inhibition triggers actionable tumour and microenvironmental remodelling in lung cancer.

Early EGFR inhibition triggers actionable tumour and microenvironmental remodelling in lung cancer.

Journal: Cancer research communications

Published: January 23, 2026

Reply to: Methodological Considerations in a Cross-Sectional Study of Cancer Knowledge and Attitudes in Jashore, Bangladesh.

Reply to: Methodological Considerations in a Cross-Sectional Study of Cancer Knowledge and Attitudes in Jashore, Bangladesh.

Journal: JCO global oncology

Published: January 09, 2026

Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025.

Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025.

Journal: Asia-Pacific journal of clinical oncology

Published: January 05, 2026

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 10, 2025

Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 28, 2025

Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC).

Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC).

Journal: Clinical genitourinary cancer

Published: October 29, 2025

Showing 1-12 of 244

Last Updated: 09/26/2026